Navigation Links
Drew Barrymore Announces US$1 Million Donation on Oprah
Date:3/3/2008

Drew Helps 'Fill The Cup' For Thousands OfKenyan School Kids

CHICAGO, March 3 /PRNewswire-USNewswire/ -- Drew Barrymore, one of the world's most recognized film stars, today announced a personal donation of US$1 million on the Oprah Winfrey Show to help the World Food Programe (WFP) feed thousands of school children in Kenya.

"I have seen with my own eyes what a difference a simple cup of nutritious porridge can make in a child's life," said Drew Barrymore. "It helps them learn, stay healthy and sets them on track for a bright future. I urge everyone -- everywhere -- to help WFP 'Fill the Cup' for hungry children, and make hunger history."

This US$1 million donation kicks off WFP's challenge to America to help feed 10 million children for a year.

"We have a dream...to feed another 10 million hungry school children in Africa by Thanksgiving Day," said Josette Sheeran, WFP Executive Director who also appeared on Oprah's show. She explained that for just 25 US cents a day, WFP can provide a school meal which feeds bodies, minds and transforms children's lives.

"Just US$50 fills a child's cup for a year, and we call on everyone to click on wfp.org and make a donation," said Sheeran.

Saying that WFP was "all action -- not talk", Barrymore, a WFP "Ambassador Against Hunger," has travelled to Kenya twice in two years to see first-hand the impact hunger has on poor children. She is an ardent advocate for WFP school meals which boost children's chances for health, education and a more promising future.

Sheeran thanked the actress for her generous personal donation to WFP, and paid tribute to her passion and commitment to changing the world for the better.

One of the schools Drew Barrymore has visited in Kenya is Stara, in Nairobi's sprawling slums where students say WFP lunches make a real difference.

"Often I come to school without anything to eat. A meal at school helps me because at ho
'/>"/>

SOURCE Friends of the World Food Program
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
2. PreMD Inc. Announces Debenture Financing
3. Caregivers are Honored as CVS/pharmacy Announces Winners of the For All the Ways You Care Contest
4. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
5. Therap Services Announces Release 7.2 for the Developmental Disability Community
6. CVS Caremark All Kids Can Program Announces the Opening of a Boundless(TM) Playground in Dallas to Serve Children of all Abilities
7. Nightingale announces US$12.3 million sale of its Therapist Helper business
8. Hillenbrand Industries, Inc. Announces Any and All Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009
9. MINRAD International, Inc. Announces the Start of the MINRAD International Distributor Meeting in Cape Town, South Africa
10. Dialysis Corporation of America Announces Fiscal Year 2007 Earnings Release Date
11. Childrens Healthcare of Atlanta Announces Major Investment in Pediatric Research as Part of 10-Year Vision
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...be the fastest growing industry, but it has been s...t fast food chains are now entirely automated, mos...heir records on paper. , In a new position paper...d/policy/ehealth.pdf ) released today by the Ameri...est medical specialty organization says that colla...
(Date:5/16/2008)...ater: An AIDS Vaccine is Possible and,Still Urgent...ire/ -- Twenty-five years since the,discovery of H...dressing,the AIDS pandemic. Scientists have learne... any other pathogen, and have developed more drugs...ned. But this progress is not,enough. While it is ...
(Date:5/16/2008)...lly Residents to Eat Right, Move More and ... 16 /PRNewswire/ -- The last decade can be defined...ich seem to go in and out of,fashion like shoulder...n,slim. Two out of three Americans -- including 30...t or obese., A new campaign crossing the country,...
(Date:5/16/2008)...cells in cord blood more than 30-fold , ,...t uses natural killer (NK) immune system cells fro...leukemia cells in mice, researchers say. , The...n acute lymphocytic leukemia (ALL) and acute myelo...essive human leukemias, according to the study. ,...
Breaking Medicine News(10 mins):Health News:New E-health recommendations from ACP aim to improve health care quality, safety, and access 2Health News:World AIDS Vaccine Day 2008 2Health News:World AIDS Vaccine Day 2008 3Health News:World AIDS Vaccine Day 2008 4Health News:Message to Michigan Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Michigan Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:New Therapy Kills Human Leukemia Cells in Mice 2
...ts may be beneficial in preventing severe long-ter...resently there exists no effective treatment for t...isability is most likely to appear. The Children...ing in the Journal of Neuroscience, and conducted...
...C, Wednesday to demand more funds for cancer resea...traveled to the rally in Washington.// She said, "...hes so many people, but on the other hand, it's em...eople willing to volunteer, give their time and th...
...nesday reported having updated the warning label o...sers about the higher risk of blood clots from it....missioned study revealed that drug users faced two... lungs compared to women taking traditional birth-...
...rpose of a sunscreen lotion as well as offers prot...searchers//, well on the threshold of a discovery;...athway that will prevent the fair skin people from...ainst cancer. Study's lead author, Dr. David E. F...
Other Medicine News:Health News:Vitamin Shots to Combat MS Pain 2Health News:Contraceptive Patch Carries Risk of Blood clots 2
(Date:5/16/2008)... NEW YORK, May 16 /- Pulmo ...ounced details of the methodology and,purpose of i...ar Imaging,technology for the diagnosis of Pulmona... will be carried out by the Pulmo BioTech subsidia...s: "Phase I Study of the Use,of PulmoBind for Mole...
(Date:5/16/2008)... BRIDGEWATER, N.J., May 16 /- Data fr...ower mean baseline hemoglobin (Hb) levels,and the ...e effect of,restrictions on reimbursement for eryt...atients on the nation,s blood supply, will be pres... (ASCO) Annual Meeting later this,month. The meeti...
(Date:5/16/2008)...ktar,s Technology Enables First-Ever PEGylation of...ted Therapeutic Activity, SAN CARLOS, Calif., May...(Nasdaq: NKTR ) announced initial results today f...ecan. The data shows significant,anti-tumor activi...tudy,also demonstrates that Nektar,s small molecul...
(Date:5/16/2008)...Single Molecule with Dual Mechanism May Offer Nove...ure Management, NEW ORLEANS, May 16 /PRNewswire-F...ator in the discovery and development of novel sma...33540, its first-in-class,Dual Acting Receptor Ant...lood pressure reductions in a Phase 2a study in pa...
Breaking Medicine Technology:Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 2Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8BioMarin to Present at the Rodman 26 Renshaw 9th Annual Healthcare Conference 1611 1Crystal Research Associates LLC Issues Executive Informational Overview 28R 29 28EIO 28R 29 29 on CEL SCI Corporation 709 1Crystal Research Associates LLC Issues Executive Informational Overview 28R 29 28EIO 28R 29 29 on CEL SCI Corporation 709 2Crystal Research Associates LLC Issues Executive Informational Overview 28R 29 28EIO 28R 29 29 on CEL SCI Corporation 709 3US government delays nanotechnology safety measures 1048 1US government delays nanotechnology safety measures 1048 2Medivation Announces Participation in Acumen BioFin Rodman 26 Renshaw 9th Annual Healthcare Conference 1605 1Medivation Announces Participation in Acumen BioFin Rodman 26 Renshaw 9th Annual Healthcare Conference 1605 2
...FirstCall/ --,Bionovo, Inc.,s lead drug candidate,...eatment of hot flashes associated with menopause.,...he company,s,double-blind, placebo- controlled, ra...50 or more moderate to severe hot flashes,per week...receiving,MF101 (5 grams/day), MF101 (10 grams/day...
...rstCall/ -- VION,PHARMACEUTICALS, INC. announced t... session at the 43rd Annual Meeting of The America...anticancer agent,Cloretazine(R) (VNP40101M) as a s...elapsed or refractory small cell lung cancer. , Th...1M) in two,separate subpopulations of small cell l...
Other Medicine Technology:Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 2Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 3Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 4Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 5Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 2Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 3Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 4
The Mitek CuffTack sutureless fixation device offers superior fixation strength for rotator cuff repairs. The implant firmly reattaches soft tissue to the bone with one step insertion. CuffTack is in
...imple to use system can be used for open or arthro... a sterile disposable inserter. The unique deploym... insertion of the anchor into bone. The Independe...lows for the two pre-threaded sutures to independe...
The Micro Anchor is the smallest, strongest anchor on the market allowing exceptional flexibility in placement into even the smallest bones. This anchor comes pre-loaded with 3-0 or 4-0 ETHIBOND EXCE
FASTIN RC is a threaded titanium anchor, specifically designed for rotator cuff procedures. The anchor features wide threads and a small core to optimize bone purchase, as well as independent suture
Medicine Products: